Manufacturing Partnerships NewAmsterdam has an active collaboration with Piramal to establish an OSD form suite, signaling strong manufacturing and supply chain considerations for its oral CETP inhibitor. Use this to approach contract development and manufacturing organizations, formulation specialists, and packaging and logistics providers to plan scalable production and global distribution for obicetrapib.

Cardiometabolic Focus The focus on LDL-C lowering for ASCVD and familial hypercholesterolemia patients inadequately managed by current therapies creates touchpoints with cardiology and lipid clinics, as well as specialty pharmacies. Opportunities include payer discussions, clinical data collaborations, and access programs to drive formulary placement and patient uptake.

Conference Outreach Regular participation in high profile healthcare conferences signals readiness to engage with potential investors, strategic partners, and key opinion leaders. Sales BD can plan targeted outreach around conference sessions, sponsor relationships, and post event follow ups with hospital systems and payers.

Licensing & Global Expansion As a late stage company with a novel oral therapy, there are opportunities to entertain co development, licensing, or regional partnerships with larger pharma to accelerate global access and scale regulatory submissions and commercialization.

Competitive Positioning Obicetrapib offers a convenient, low dose oral option for statin intolerant patients, presenting a compelling value proposition for payers and clinicians emphasizing tolerability and ease of use. BD outreach should tailor value based messaging, generate real world evidence, and connect with lipid clinics and ACC networks to support adoption.